Ardelyx, Inc.
NGM: ARDXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Ardelyx, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ARDX Z-Score →About Ardelyx, Inc.
Healthcare
Biotechnology
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
📊 Fundamental Analysis
Ardelyx, Inc. demonstrates a profit margin of -15.1%, which is below the sector average, suggesting competitive pressure.
The company recently reported 7.8% revenue growth, which is modest compared to its industry peers.
Return on Equity (ROE) is -36.2%, which indicates that capital utilization is currently under pressure.
At a current price of $6.18, ARDX currently sits at the 57th percentile of its 52-week range (Range: $3.21 - $8.40).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$1.52B
Trailing P/E
--
Forward P/E
11.84
Beta (5Y)
0.66
52W High
$8.40
52W Low
$3.21
Avg Volume
3.97M
Day High
Day Low